Skip to main content
. 2021 Oct 23;15(1):123–131. doi: 10.1016/j.jiph.2021.10.021

Table 2.

COVID-19 vaccines patents/applications filed by key players.

Patent/application number
(Date of patent/publication)
Summary of claims Ref. No.
Moderna
US10703789B2
(July 7, 2020)
A pharmaceutical composition (vaccine) comprising lipid nanoparticles containing an mRNA encoding a polypeptide that can be used as a vaccine. [78]
US10702600B1
(July 7, 2020)
A vaccine composition comprising a mRNA containing an open reading frame encoding a beta-coronavirus (Beta-CoV) S protein or S protein subunit formulated in a lipid nanoparticle. [79]
US10064959B2
(September 4, 2018)
A synthetic mRNA, which is effective as a vaccine when administered to a mammalian subject. [80]
US10933127B2
(March 2, 2021)
A method of inducing an immune response to the Beta-CoV S protein or S protein subunit in a mammal using a mRNA containing an open reading frame encoding a Beta-CoV S protein or S protein subunit formulated in a lipid nanoparticle in an effective amount. [81]
BioNTech
US20190321458A1
(October 24, 2019)
A vaccine composition comprising a single-stranded RNA containing an open reading frame encoding a peptide or protein of interest, and polyalkyleneimine (polyethylenimine and/or polypropylenimine). [82]
US10729785B2
(August 4, 2020)
A method of immunity stimulation against an infectious disease using a vaccine composition comprising protamine 1000/5000, a mRNA, and at least one endosome destabilizing agent. [83]
Curevac
WO2021123332A1
(June 24, 2021)
A method of treatment or prophylaxis of infectious diseases (COVID-19) using a vaccine of mRNA. [84]
US20210023199A1
(January 28, 2021)
A method of stimulating an antigen-specific immune response in a human subject comprising administering to the subject an effective amount of a vaccine composition containing a mRNA encoding a spike protein (S) from a SARS-CoV. [85]
US20210060175A1
(March 4, 2021)
A method of stimulating an immune response in a subject comprising administering an effective amount of a vaccine composition comprising a purified mRNA encoding a SARS-CoV antigen to the subject. [86]
Janssen Pharmaceuticals
WO2021155323A1
(August 5, 2021)
A vaccine against COVID-19 to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older, comprising a recombinant human adenovirus of serotype 26 that contains nucleic acid encoding a SARS-CoV-2 S protein or fragment thereof. [87]
CA3101131A1
(July 31, 2021)
A vaccine comprising a recombinant human adenovirus of serotype 26 that comprises a nucleic acid encoding a SARS-CoV-2 S protein. [88]
Inovio Pharmaceuticals
US10548971B2
(February 4, 2020)
An immunogenic vaccine composition comprising a nucleic acid molecule of a specific sequence for inducing an immune response against a coronavirus infection. [89]
Gamaleya
EA037297B1
(March 5, 2021)
A pharmaceutical agent of specific sequence ID for the induction of specific immunity against SARS-CoV-2. [90]
EA037291B1
(March 5, 2021)
An expression vector containing the genome of the recombinant human adenovirus to create an immunobiological agent for the induction of specific immunity against SARS-CoV-2. [91]
RU2731342C1
(September 1, 2020)
A pharmaceutical agent of specified sequence ID for the induction of specific immunity against SARS-CoV-2. [92]
Novavax
WO2021154812A1
(August 5, 2021)
A vaccine composition comprising coronavirus Spike glycoprotein of specific sequence ID to stimulate an immune response against SAR.S-CoV-2 in a subject. [93]
US10953089B1
(March 23, 2021)
An immunogenic vaccine composition comprising a nanoparticle containing a coronavirus S glycoprotein having a specific amino acid sequence. [94]